諾誠健華(09969)：奧布替尼在澳大利亞獲批用於治療復發或難治性套細胞淋巴瘤

　　諾誠健華(09969)(滬:688428)公布，奧布替尼已獲澳大利亞藥品管理局(TGA)批准，用於治療復發或難治性套細胞淋巴瘤(r/r MCL)成年患者。MCL屬於B細胞非霍奇金淋巴瘤(NHL)的特殊亞型，是一種侵襲性強、目前臨床難以根治且發病率不斷上升的疾病。患者確診時多已進展至晚期，臨床治療方案有限且整體預後不佳。
《經濟通通訊社27日專訊》

【你點睇？】香港高溫破142年歷史紀錄，林超英批暑熱警告形同虛設，你是否贊成現行的工作暑熱警告制度進行檢討？ ► 立即投票

回頁頂

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。